Ambit Announces Participation At Jefferies 2014 Global Healthcare Conference

By PR Newswire,  May 28, 2014, 07:30:00 AM EDT


SAN DIEGO, May 28, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ:AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Jefferies 2014 Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on June 2-5, 2014.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 10:30 a.m. ET on Tuesday, June 3, 2014.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available until July 3, 2014 following the initial presentation webcast. 

About Ambit Biosciences

Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently in a registrational Phase 3 clinical trial, referred to as QUANTUM-R, in patients with relapsed/refractory acute myeloid leukemia (AML).  Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Ambit Contacts:



Marcy Graham

Andrew McDonald, Ph.D.

Executive Director, Investor Relations & Corp Comm

LifeSci Advisors, LLC  

Ambit Biosciences Corporation

Founding Partner

858-334-2125

646-597-6987

mgraham@ambitbio.com  

andrew@lifesciadvisors.com

 

 

 

SOURCE Ambit Biosciences



This article appears in: News Headlines

Referenced Stocks: AMBI


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
FTR $ 6.79 0.85 ▲ 14.31%
WIN $ 11.83 1.30 ▲ 12.35%
SIRI $ 3.40 0.02 ▲ 0.59%
T $ 36.59 0.94 ▲ 2.64%
CTL $ 39.90 2.19 ▲ 5.81%
BAC $ 15.34 0.16 ▼ 1.03%
RAD $ 6.56 0.13 ▼ 1.94%
AAPL $ 98.38 0.64 ▼ 0.65%

As of 7/29/2014, 04:04 PM